Arimoclomol for treating glucocerebrosidase associated disorders

Abstract

The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders.

1 . A method of increasing glucocerebrosidase (GBA) level and/or activity in a cell, comprising:
 contacting the cell with an active pharmaceutical ingredient selected from: N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, a stereoisomer thereof, and an acid addition salt thereof.   
     
     
         2 . The method of  claim 1 , wherein the cell has reduced levels and/or activity of GBA compared to a control. 
     
     
         3 . The method of  claim 2 , wherein the cell has one or more GBA gene mutations. 
     
     
         4 . The method of  claim 3 , wherein the GBA gene mutation is homozygous. 
     
     
         5 . The method of  claim 3 , wherein the GBA gene mutation is heterozygous. 
     
     
         6 . The method of  claim 3 , wherein the GBA gene mutation is compound heterozygous. 
     
     
         7 . The method of  claim 3 , wherein the GBA gene mutation is selected from the group consisting of L444P, D409H, D409V, E235A, E340A, E326K, N370S, N370S/1-BP ins 84G, V394L, A456P, V460V, C342G, G325R, P415R, Y133*, F213I, N188S, and IVS2+1G>A/N188S. 
     
     
         8 . The method of  claim 2 , wherein the reduced levels and/or activity of GBA is idiopathic. 
     
     
         9 . The method of  claim 1 , wherein the active pharmaceutical ingredient:
 i) is a racemate of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride; or   ii) is an optically active stereoisomer of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride; or   iii) is an enantiomer of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride; or   iv) is selected from the group consisting of (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, and (−)-(S)-N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride; or   v) is an acid addition salt of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride; or   vi) is selected from the group consisting of N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate, and N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride maleate; or   vii) is selected from the group consisting of (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate; (−)-S—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride citrate; (+)-R—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride maleate; and (−)-S—N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride maleate.   
     
     
         10 . The method of  claim 1 , wherein the cell is in vitro or in vivo. 
     
     
         11 . The method of  claim 1 , wherein the GBA level and/or activity is increased at least 1.5-fold. 
     
     
         12 . The method of  claim 1 , wherein the GBA level and/or activity is increased at least 10%.